Meeting Banner
Abstract #4862

A multicenter in vivo study to evaluate gadoxetate DCE-MRI as a preclinical biomarker of liver function

Paul Hockings1,2, Anastassia Karageorgis3, Stephen Lenhard4, Brittany Yerby5, Mikael Forsgren6,7, Serguei Liachenko8, Edvin Johansson3, Richard Peterson9, Xi Yang8, Dominic Williams10, Sharon Ungersma5, Ryan Morgan5, Kim Brouwer11, and Beat Jucker4

1Antaros Medical, Molndal, Sweden, 2MedTech West, Chalmers University of Technology, Gothenburg, Sweden, 3AstraZeneca, Molndal, Sweden, 4GlaxoSmithKline, King of Prussia, PA, United States, 5Amgen Inc., Thousand Oaks, CA, United States, 6Linköping University, Linköping, Sweden, 7Wolfram MathCore, Linköping, Sweden, 8National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, United States, 9AbbVie, North Chicago, IL, United States, 10AstraZeneca, Cambridge, United Kingdom, 11University of North Carolina, Chapel Hill, NC, United States

Gadoxetate dynamic contrast-enhanced MRI (DCE-MRI) seems promising for non-invasive quantification of liver function. Here we tested the reproducibility of gadoxetate DCE-MRI at four MRI sites using an acute clinical dose of the antibiotic rifampicin. We found significant differences between sites in maximum relative enhancement (RE) in vehicle treated rats. However, highly significant differences in maximum RE between vehicle and rifampicin treated rats was detected at all sites. To our knowledge this is the first multicenter preclinical reproducibility study of an imaging biomarker.

This abstract and the presentation materials are available to members only; a login is required.

Join Here